Punicalagin treats postmenopausal osteoporosis by promoting osteogenesis
Zhang Shudong1, Huang Yilin1, Yao Qi2
1Second Department of Orthopedics, The First Affiliated Hospital of Henan University, Kaifeng 475000, Henan Province, China; 2Department of Joint, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
Abstract: BACKGROUND: Punicalagin has a wide range of effects and high safety, but its effect on osteoblasts and postmenopausal osteoporosis is unknown.
OBJECTIVE: To investigate the effect of punicalagin on osteoblasts and postmenopausal osteoporosis.
METHODS: The effect of punicalagin on the proliferation of MC3T3-E1 cells was detected. Punicalagin was added to the osteogenic induction medium to detect its effect on osteogenic differentiation. Punicalagin was used to treat ovariectomized rats and Micro CT scan and serum procollagen type 1 N-terminal propeptide test were performed after 3 months to detect the therapeutic effect.
RESULTS AND CONCLUSION: Cell counting kit-8 assay showed that punicalagin could promote the proliferation of osteoblasts (P < 0.05). The results of qRT-PCR and western blot showed that punicalagin could promote the mRNA and protein expressions of alkaline phosphatase and Runx2 in osteoblasts (P < 0.05). The results of Micro CT scan and serological test showed that punicalagin could improve bone mineral density, bone volume fraction, trabecular thickness, trabecular number and procollagen type 1 N-terminal propeptide level of ovariectomized rats. To conclude, punicalagin can promote osteoblast proliferation and differentiation, and have therapeutic effects in postmenopausal osteoporosis rats.
Key words: punicalagin, postmenopausal osteoporosis, ovariectomy, osteoblast, procollagen type 1 N-terminal propeptide